<DOC>
	<DOCNO>NCT02924727</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety LCZ696 titrate target dose 200 mg twice daily , compare ramipril titrate target dose 5 mg twice daily , addition conventional post-AMI treatment , reduce occurrence composite endpoint CV death , HF hospitalization outpatient HF ( time-to-first event analysis ) post-AMI patient evidence LV systolic dysfunction and/or pulmonary congestion , know prior history chronic HF..</brief_summary>
	<brief_title>Prospective ARNI v ACE Inhibitor Trial DetermIne Superiority Reducing Heart Failure Events After MI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age . 2 . Diagnosis spontaneous AMI base universal MI definition* randomization occur 12 hour 7 day index event presentation . 3 . Evidence LV systolic dysfunction and/or pulmonary congestion require intravenous treatment associate index MI event define : LVEF ≤40 % index MI presentation prior randomization and/or Pulmonary congestion require intravenous treatment index hospitalization 4 . At least one follow 8 risk factor : Age ≥ 70 year eGFR &lt; 60 mL/min/1.73 m2 base MDRD formula screen visit Type I II diabetes mellitus Documented history prior MI Atrial fibrillation note ECG , associate index MI LVEF &lt; 30 % associate index MI Worst Killip class III IV associate index MI require intravenous treatment STEMI without reperfusion therapy within first 24 hour presentation 5 . Hemodynamically stable define : SBP ≥ 100 mmHg randomization patient receive ACEi/ARB last 24 hour prior randomization SBP ≥ 110 mmHg randomization patient receive ACEi/ARB last 24 hour prior randomization No IV treatment diuretic , vasodilator , vasopressor and/or inotropes 24 hour prior randomization Key 1 . Known history chronic HF prior randomization 2 . Cardiogenic shock within last 24 hour prior randomization 3 . Persistent clinical HF time randomization 4 . Coronary artery bypass graft ( CABG ) perform planned index MI 5 . Clinically significant right ventricular MI index MI 6 . Symptomatic hypotension screen randomization 7 . Patients known history angioedema 8 . Stroke transient ischemic attack within one month prior randomization 9 . Known suspected bilateral renal artery stenosis 10 . Clinically significant obstructive cardiomyopathy 11 . Openheart surgery perform within one month prior randomization plan cardiac surgery w/in 3 month prior randomization 12. eGFR &lt; 30 ml/min/1.73 m2 measure MDRD screen 13 . Serum potassium &gt; 5.2 mmol /L screen 14 . Known hepatic impairment ( evidenced total bilirubin &gt; 3.0 mg/dL increase ammonia level , perform ) , history cirrhosis evidence portal hypertension varix 15 . Previous use LCZ696 EntrestoTM 16 . History malignancy organ system ( localize basal cell carcinoma skin ) within past 3 year life expectancy less 1year . 17 . History hypersensitivity study drug drug similar chemical class know intolerance contraindication study drug drug similar chemical class include ACE inhibitor , ARB NEP inhibitor 18 . Pregnant nursing woman woman childbearing potential unless use highly effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Spontaneous AMI</keyword>
	<keyword>HF hospitalization</keyword>
	<keyword>outpatient HF</keyword>
	<keyword>LV systolic dysfunction</keyword>
	<keyword>pulmonary congestion</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>randomize clinical trial</keyword>
	<keyword>LCZ696</keyword>
	<keyword>ramipril</keyword>
</DOC>